Equillium (NASDAQ:EQ) Azioni

Equillium

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Equillium Inc

Invesco Russell 1000 Equal Weight ETF

EQT AB

Equity Bancshares, Inc. Class A Common Stock

Equity Bancshares Inc

Mensa Mining Corp

Equity Commonwealth Common Shares of Beneficial Interest

Equity Commonwealth

EQUITABLE FINCL CORP by Equitable Financial Corp.

Equitable Financial Corp

EQB Inc

Equitable Holdings Inc

Equitable Holdings, Inc. Depositary Shares

Equitable Holdings, Inc. Depositary Shares, each representing a 1/1,000th interest in a share of Fixed Rate Noncumulative Perpetual Preferred Stock, Series C

Columbia U.S. Equity Income ETF

EQUINITI GROUP PLC ADR by Equiniti Group PLC

Equinix Inc

ALPS Equal Sector Weight ETF

EQ Labs Inc

Simplify Exchange Traded Funds Simplify Market Neutral Equity Long/Short ETF

iShares Trust iShares MSCI Emerging Markets Quality Factor ETF

EQUITY METALS CORPORATION by Equity Metals Corporation

Equity Metals Corp

Equinor ASA

EQUINOX RES LTD by EQUINOX RES LTD

Eqonex Ltd Ordinary Shares

Equity Residential Common Shares of Beneficial Interest

Equity Residential

ProShares Equities for Rising Rates ETF

EQRX INC COM

EQRX INC WT EXP

Equus Total Return Inc

EQS GROUP AG by EQS GROUP AG

EQT Corp

Equal Trading Inc

EQM Technologies & Energy Inc Com

EQUITECH INTL CORP by Equitech Int'l Corp.

Equitech International Corp

Equitrans Midstream Corp PRF PERPETUAL USD - Ser 4/A2

ALTAMIRE GOLD CORP ORD by Altamira Gold Corp

Altamira Gold Corp

Lake Winn Resources Corp

LAKE WINN RESOURCES CORP by Lake Winn Resources Corp

Valued Advisers Trust Kovitz Core Equity ETF

QuadrantProtocol

EQUATORIAL ENERGIA S/ADR by Equatorial Energia S.A.

Equatorial SA

IndexIQ ETF Trust NYLI Engender Equality ETF

E-Qure Corp

EQV Ventures Acquisition Corp. Class A Ordinary Shares

EQV Ventures Acquisition Corp

EQV Ventures Acquisition Corp. Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant

EQV Ventures Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share

Invesco S&P 100 Equal Weight ETF

Equinox Gold Corp

Equalizer

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) with a Buy and lowers the price target from $75 to $50.

News

Price Target

Analyst Ratings

NDRA

Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $50

New parents are raising concerns that President Donald Trump&#8217;s tariffs could significantly drive up the cost of baby care products. What Happened: Sam Rutledge and his wife, who are expecting a baby in mid-July, have fast-tracked their purchases of baby gear due to the tariff announcement in early April.
The couple has bought two strollers, a car seat, a nursery glider, a crib, and a high chair, all of which are made overseas. &#8220;These are all pretty expensive under normal conditions, but when it became clear tariffs were coming we decided to buy them in case they became prohibitively expensive,&#8221; Rutledge said, according to <a href="https://fortune.com/article/new-parents-worried-trump-tariffs-will-make-having-baby-prohibitively-expensive/">a</a> report by Fortune.
The&nbsp;Juvenile Products Manufacturers Association, a&nbsp;U.S. trade group, estimates that&nbsp;90% of the core baby&nbsp;care products and their parts are made in Asia, with the majority coming from China. The tariffs, ranging&nbsp;from 10% for imports from&nbsp;most countries to 145% for&nbsp;imports from China, could significantly increase the cost for new parents.
Steven Dunn, CEO of Munchkin Inc., has halted orders from China and instituted a hiring freeze at the company&#8217;s California headquarters in response to the tariffs. Dunn expects Munchkin will run out of some products within three months. &#8220;There is no possibility of being able to pass on those tariffs&#8221; to customers in the form of price increases, he said.
See Also:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/04/44891509/bitcoin-crosses-key-barrier-dogecoin-spikes-ethereum-flat-on-easter-sunday-popular-influencer-says-btc-needs-to-breach-88804-for-a-bullish-breakout" target="_blank" rel="noreferrer noopener">Bitcoin Crosses Key Barrier, Dogecoin Spikes, Ethereum Flat On Easter Sunday: Popular Influencer Says BTC Needs To Breach $88,804 For A Bullish Breakout &#8211; Grayscale Bitcoin Mini Trust (BTC) Common uni</a>
Many baby brands and companies have declined to comment on the tariffs.&nbsp;The Juvenile Products Manufacturers Association&nbsp;has&nbsp;asked the Trump administration for&nbsp;a tariff exemption, arguing that&nbsp;baby products are essential for&nbsp;children&#8217;s well-being.
Why It Matters: The tariffs, part of Trump&#8217;s strategy to stimulate domestic investment by companies seeking to evade import taxes, took effect in early April. The&nbsp;<a href="https://www.benzinga.com/news/global/25/04/44632479/retail-stocks-slammed-as-trumps-tariff-plan-sends-shockwaves-through-sector?">retail sector</a>&nbsp;was hit hard, with stocks under heavy selling pressure as Wall Street digested the tougher-than-anticipated tariff plan.
Former Secretary of the Treasury Lawrence H. Summers described <a href="https://www.benzinga.com/25/04/44622754/tariffs-are-most-expensive-and-masochistic-could-cost-30-trillion-to-the-economy-erasing-300k-per-family-explains-former-treasury-secretary-larry-summers">the tariffs as the "most expensive and masochistic" </a>move by the U.S., which could roil the economy, erasing trillions of dollars. According to him, the stock futures fell 2-3% after Trump&#8217;s announcement, erasing about $1.5 trillion, and the market had already priced in some of the impact.
With the majority of baby care products being imported from Asia, particularly China, the tariffs could significantly increase the cost for new parents, making essential baby care items unaffordable. Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44891607/el-salvadors-nayib-bukele-proposes-swapping-us-deported-venezuelans-with-nicolas-maduros-political-prisoners-vene" target="_blank" rel="noreferrer noopener">Nayib Bukele Proposes Swapping US-Deported Venezuelans With Nicolas Maduro&#8217;s &#8216;Political Prisoners&#8217;</a></li>
</ul>
Photo Courtesy: Joshua Sukoff on Shutterstock.com

Politics

Economics

Trump's Tariffs Add Financial Strain for New Parents Amid Rising Baby Gear Costs

Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.15 by 8.7 percent. This is a 27.55 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $829.00 million which missed the analyst consensus estimate of $831.34 million by 0.28 percent. This is a 5.74 percent increase over sales of $784.00 million the same period last year.

Earnings

Comerica Q1 2025 GAAP EPS $1.25 Beats $1.15 Estimate, Sales $829.00M Miss $831.34M Estimate

B. Riley Securities analyst Craig Ellis downgrades Axcelis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) from Buy to Neutral and lowers the price target from $80 to $50.

Downgrades

ACLS

B. Riley Securities Downgrades Axcelis Technologies to Neutral, Lowers Price Target to $50

On Thursday, April 17, U.S. markets closed mixed as investors balanced progress in trade talks with ongoing concerns about interest rates. Optimism followed positive comments on trade negotiations, but uncertainty remained about future deals. While some sectors saw gains, the broader market experienced declines over the week. Traders are focused on upcoming trade discussions and potential actions from the central bank.
In economic data, U.S. housing starts decreased by 11.4% month-over-month to an annualized rate of 1.324 million in March. Initial jobless claims fell by 9,000 to 215,000 in the second week of April, better than the expected 225,000. The Philadelphia Fed Manufacturing Index dropped by 39 points to -26.4 in April, well below the expected 2.
Most sectors on the S&amp;P 500 closed higher, led by energy, consumer staples, and real estate, while information technology and healthcare ended lower.
The Dow Jones Industrial Average declined 1.33% to 39,142.23, the S&amp;P 500 rose 0.13% to 5,282.70, and the Nasdaq Composite slid 0.13% to close at 16,286.45.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 fell 1.30% to close at 34,279.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.</li>
<li>Australian markets are closed for the Easter holiday.</li>
<li>India&#8217;s Nifty 50 was up 1.11% at 24,119.25, and Nifty 500 rose 1.45% to 21,994.95.</li>
<li>China&#8217;s Shanghai Composite rose 0.45% to 3,291.43, while Shanghai Shenzhen CSI 300 gained 0.33% to 3,784.88.</li>
<li>Hong Kong markets are closed for the Easter holiday.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>European markets closed for the Easter holiday.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 2.91% at $62.15/bbl, and Brent was down 2.80% at $66.05/bbl.</li>
<li>Oil prices dropped on Monday amid positive U.S.-Iran talks and concerns over an economic slowdown caused by tariffs. Lower liquidity and fears of reduced fuel demand heightened market volatility.</li>
<li>Natural Gas fell 0.96% to $3.216.</li>
<li>Gold was trading higher by 2.34% at $3,406.26, Silver was up 1.12% to $32.835, and Copper rose 0.87% to $4.7803.</li>
<li>Gold prices hit a new record on Monday, rising due to a weaker dollar, geopolitical tensions, and uncertainty surrounding U.S. Federal Reserve policy.        </li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.98%, S&amp;P 500 futures declined 1.12% and Nasdaq 100 futures fell 1.20%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index slipped 1.29% to 99.19, USD/JPY was down 1.07% to 140.65, and USD/AUD fell 0.18% to 1.5653.</li>
<li>The dollar fell sharply on Monday, hitting decade-lows against the Swiss franc and yen, as concerns grew over President Trump&#8217;s plans to challenge the independence of the Federal Reserve.</li>
</ul>
Photo by FOTOGRIN via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Gold Rallies To Record, Dollar Drops - Global Markets Today While US Slept

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) with a Buy and lowers the price target from $75 to $60.

CING

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $60

Mizuho analyst Uy Ear initiates coverage on Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) with a Outperform rating and announces Price Target of $51.

Initiation

TECX

Mizuho Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $51

<ul>
<li>ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis</li>
<li>Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets</li>
<li>ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process</li>
<li>Special Meeting of Stockholders for both companies to be held May 13, 2025</li>
</ul>

ALMS

SLRN

Alumis And ACELYRIN Finalize Amended Merger Deal; New Terms Offer Greater Stake For ACELYRIN Shareholders

TORONTO, April 21, 2025 /CNW/ - Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNL#TSX">CNL</a>) ("Collective" or the "Company") is pleased to announce changes in the executive management of the Company effective immediately with the appointment of Ned Jalil as Chief Executive Officer, and former CEO Omar Ossma retaining his role as President and continuing to perform his same duties within the day-to-day operations of the Company.
 &nbsp;

Management

TSX:CNL

Collective Mining Names Ned Jalil CEO, Effective Immediately

Morgan Stanley analyst Benjamin Swinburne downgrades Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Overweight to Equal-Weight and lowers the price target from $37 to $32.

Morgan Stanley Downgrades Warner Music Gr to Equal-Weight, Lowers Price Target to $32

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule").
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, 2025, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until April 13, 2025, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company's request for continued listing.
The Notice has no immediate effect on the listing or trading of the Company's common shares.
The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.

Government

Regulations

AFMD

Affimed Receives Nasdaq Notice Over Low Share Price, Has Until October to Regain Compliance

Chicago Fed President Austan Goolsbee has voiced serious concerns over President Donald Trump's recent remarks about removing Federal Reserve Chair Jerome Powell. What Happened: Trump's comments, made following <a href="https://fortune.com/2025/04/16/jerome-powell-tariffs-inflation-economy/">Powell's speech</a> at the Economic Club of Chicago, reignited a long-standing debate over the President's power to remove Federal Reserve leaders.
Goolsbee warned that such an action could severely undermine the credibility of the U.S. central bank, with far-reaching consequences for economic stability, as reported <a href="https://fortune.com/article/chicago-fed-president-austan-goolsbee-trump-terminate-jerome-powell-undermine-fed-credibility/">by</a> Fortune on Monday.
Trump has repeatedly criticized Powell for not cutting interest rates quickly enough in response to economic conditions, particularly following his controversial tariff policies.
Powell has argued that the tariff increases announced by Trump have significantly impacted inflation and economic growth, which led to his warnings.
Trump has blamed Powell for not acting swiftly enough to ease interest rates, which he believes are necessary to counter the negative economic effects of his policies.
See Also: <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44883642/peter-schiff-rings-alarm-after-foreign-investors-dump-6-5-billion-in-us-equities-in" target="_blank" rel="noreferrer noopener">Peter Schiff Rings Alarm After Foreign Investors Dump $6.5 Billion In US Equities In A Week, Quips &#8216;Trump Thought Tariffs Would Bring Capital Into America&#8217;</a>
This conflict has drawn attention. Goolsbee, echoing the concerns of many economists, cautioned that removing Powell could set a dangerous precedent that could erode trust in the Fed.
"I strongly hope that we do not move ourselves into an environment where monetary independence is questioned," Goolsbee stated, highlighting the importance of keeping the Federal Reserve free from political influence.
Why It Matters: Trump&#8217;s criticism of Powell and his intention to terminate him have been a topic of concern for some time. Trump <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44861571/donald-trump-blasts-too-late-and-wrong-fed-chair-powell-but-polymarket-traders-doubt-his-termination-will-come-fast-enough">lashed out at Powell</a> for the Federal Reserve&#8217;s reluctance to cut interest rates.
This was followed by <a href="https://www.benzinga.com/markets/25/04/44883756/warren-foresees-market-turmoil-if-trump-dismisses-feds-powell-if-powell-can-be-fired-by-trump-it-will-crash-markets">Senator Elizabeth Warren&#8217;s warning</a> about a potential stock market collapse if Trump decides to fire Powell.
Investment strategists have also&nbsp;<a href="https://www.benzinga.com/news/25/04/44882256/trumps-threat-to-fire-powell-could-shake-us-financial-markets">warned</a>&nbsp;that Trump&#8217;s potential attempt to dismiss Powell could rattle U.S. financial markets and undermine central bank independence. Furthermore,&nbsp;<a href="https://www.benzinga.com/25/04/44888232/trumps-top-economic-adviser-kevin-hassett-says-white-house-is-exploring-options-to-fire-fed-chair-jerome-powell-the-president-and-his-team-will-continue-to-study">White House National Economic Council chair Kevin Hassett</a>&nbsp;confirmed that the Trump administration is exploring ways to remove Powell, adding to the uncertainty. Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44891314/dhl-says-its-suspending-global-shipments-to-us-valued-more-than-800-as-customs-updates-cause-multi-day-transit-de" target="_blank" rel="noreferrer noopener">DHL Says It&#8217;s Suspending Global Shipments To US Valued More Than $800 As Customs Updates Cause Multi-Day Transit Delays</a></li>
</ul>
Photo courtesy: Domenico Fornas / Shutterstock.com

Chicago Fed President Expresses Concern Over Trump's Intention To Dismiss Jerome Powell

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Market Perform and lowers the price target from $47 to $42.

FITB

Keefe, Bruyette & Woods Maintains Market Perform on Fifth Third Bancorp, Lowers Price Target to $42

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains First Finl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>) with a Market Perform and lowers the price target from $38 to $36.

FFIN

Keefe, Bruyette & Woods Maintains Market Perform on First Finl Bankshares, Lowers Price Target to $36

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and raises the price target from $19 to $20.

PSTV

Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) with a Market Perform and lowers the price target from $75 to $73.

BANR

Keefe, Bruyette & Woods Maintains Market Perform on Banner, Lowers Price Target to $73

Keefe, Bruyette &amp; Woods analyst Kelly Motta upgrades F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) from Market Perform to Outperform and maintains the price target from $16.5 to $16.5.

Upgrades

Keefe, Bruyette & Woods Upgrades F N B to Outperform, Maintains Price Target to $16.5

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) with a Buy and raises the price target from $19 to $19.5.

PAVM

Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $19.5

Baird analyst Jonathan Komp upgrades Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) from Neutral to Outperform and maintains the price target from $15 to $15.

Baird Upgrades Wolverine World Wide to Outperform, Maintains Price Target to $15

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and raises the price target from $7 to $7.5.

Comments

Equillium

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO